CLL Coverage from Every Angle

Hematopoietic Cell Transplantation for TP53-Mutant or Deleted CLL: Long-Term Outcomes

By: Sarah Campen, PharmD
Posted: Monday, September 28, 2020

The sequence of alemtuzumab-based remission induction and allogeneic hematopoietic cell transplantation (alloHCT) for patients with TP53-mutant or -deleted chronic lymphocytic leukemia (CLL) in their first remission was the “most promising” treatment approach of a prospective observational study that began a decade ago. However, the treatment is outdated in the light of today’s treatment options for patients with TP53-mutant or -deleted CLL, according to Peter Dreger, MD, of the University of Heidelberg, Germany, and colleagues. They presented the long-term outcomes of the study in Bone Marrow Transplantation.

Although newer treatment options—including Bruton’s tyrosine kinase inhibitors or B-cell lymphoma 2 inhibitors—are now preferable, “our data indicate that remission induction with alemtuzumab prior to alloHCT should not be excluded for patients with relapsed/refractory TP53-mutant or -deleted CLL who lack better options,” stated the authors.

The final analysis of the study included data from 39 patients with a median age of 59 years who were enrolled between 2010 and 2012. At last follow-up, 19 patients were alive, with a median follow-up of 6 years; of these patients, 11 had minimal residual disease–negative disease at last assessment.

The cause of death in seven patients was related to graft-versus-host disease (GVHD) with or without concomitant infection. Patients who had experienced acute GVHD grades II to IV or chronic GVHD had a significantly lower risk of relapse (P = .01).

“Notably, the best subgroup consisted of 10 patients who had received alemtuzumab with or without high-dose corticosteroids for remission induction and proceeded to alloHCT in [the] first remission,” stated the authors.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.